Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver condition that can follow very different paths among patients. Although fibrosis is a key indicator, some patients without advanced fibrosis can still develop serious liver-related events. This variation led researchers to investigate whether distinct clinical subtypes of MASLD could reveal additional clues about disease progression and risk.